Prothena Corporation is a clinical-stage biotechnology company with a portfolio of novel monoclonal antibodies that may offer new treatments for diseases associated with protein misfolding or cell adhesion. 

Harnessing the power of the immune system to fight progressive disease

Latest News

CEO Dale Schenk discusses Prothena's proprietary programs
with Bloomberg TV

Discusses development of treatments for Alzheimer's and Parkinson's diseases with Olivia Sterns on Bloomberg's "In the Loop".
June 6, 2013